Tenax Therapeutics, Inc.
NASDAQ:TENXBiotechnology
+$0.10 today
- Market cap
- $50.66M
- Beta
- 0.97
- P/E (TTM)
- -9.4
- EPS (TTM)
- -$1.28
Volume 0.70M
Average 0.62M
Returns on capital
Tenax Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-54.2%
avg -231.5%
ROIC
-58.1%
avg -203.6%
ROA
-50.5%
avg -147.7%
Analysis
ROA is currently the strongest return metric at -50.5% versus its period average of -147.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Christopher T. Giordano | Chief Executive Officer, President & Director | USD 813.63K | 51 | — | — |
Stuart Rich | Chief Medical Officer & Director | USD 490.22K | 76 | 250.00K | 1.45% |
Thomas A. McGauley | Principal Financial Officer & Principal Accounting Officer | USD 475.5K | 53 | — | — |
So-Young Kim | Executive Vice President of Clinical Development & Strategy | — | — | — | — |
Douglas Hay | Executive Vice President of Regulatory Affairs | — | — | — | — |
Doug Randall | Chief Business Officer | — | — | — | — |
Thomas R. Staab | Chief Financial Officer | — | 58 | — | — |
Timothy G. Healey | Chief Commercial Officer | — | 60 | — | — |
Compensation is shown in the reported currency; data updated Oct 3, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jan 9, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
18
$5.04M
Sells
0
$0.00
Net Transaction Value
+$5.04M
Net buying
Most Active
ADAR1 Capital Management, LLC
7 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Sep 16, 26Sep 16, 2026 | Doogan Declan Direct | Buy | $101.8K$101,760.00 |
| Sep 15, 26Sep 15, 2026 | Giordano Christopher Thomas Direct | Buy | $8.8K$8,837.19 |
| Sep 11, 26Sep 11, 2026 | Giordano Christopher Thomas Direct | Buy | $11.3K$11,250.00 |
| Sep 11, 26Sep 11, 2026 | STAAB THOMAS R II Direct | Buy | $11K$10,981.13 |
| Sep 3, 26Sep 3, 2026 | ADAR1 Capital Management, LLC Indirect | Buy | $1.6M$1,604,160.00 |
| Sep 2, 26Sep 2, 2026 | ADAR1 Capital Management, LLC Indirect | Buy | $337.6K$337,585.64 |
| Sep 1, 26Sep 1, 2026 | ADAR1 Capital Management, LLC Indirect | Buy | $321.6K$321,570.26 |
| Aug 31, 26Aug 31, 2026 | ADAR1 Capital Management, LLC Indirect | Buy | $722.6K$722,593.88 |
| Aug 24, 26Aug 24, 2026 | ADAR1 Capital Management, LLC Indirect | Buy | $188.4K$188,355.47 |
| Aug 21, 26Aug 21, 2026 | ADAR1 Capital Management, LLC Indirect | Buy | $1.3M$1,266,253.84 |
1–10 of 18
Summary
Insiders reported 18 buys worth $5.04M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $5.04M. ADAR1 Capital Management, LLC was the most active insider with 7 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Tenax Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about TENX's management, answered from reported figures.
Who manages TENX?
Tenax Therapeutics, Inc. (TENX) lists 8 active executives. The top listed executive is So-Young Kim, Executive Vice President of Clinical Development & Strategy.
Are TENX insiders buying or selling?
Recent insider activity shows net buying of $48.34M.
Continue the stock analysis
Jump to another research area for this company.